iBio will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, 8-10 September 2026.
Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, will take part in a fireside chat on Tuesday, 8 September at 4:30 p.m. ET. Felipe Duran, Chief Financial Officer, will be available with Dr. Brenner for one-on-one investor meetings during the conference; to request a meeting, the company provided the investor relations email ir@ibioinc.com.
A livestream of the presentation will be available, and a replay will be posted on the investor relations section of iBio’s website for 90 days following the event.
According to the company, iBio is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer and other hard-to-treat conditions.
The company claims it combines advanced antibody engineering with AI-driven discovery to advance a differentiated pipeline and to accelerate development timelines.
